- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Nov 2025 | 24 Oct 2025 |
| Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 inter alia to consider and approve Intimation of Board meeting The Board of Directors of the Company at its meeting held today, November 5, 2025, has, inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. (As Per BSE Announcement Dated on: 05/11/2025) | ||
| Board Meeting | 4 Aug 2025 | 23 Jul 2025 |
| Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2025 inter alia to consider and approve Intimation of Board Meeting for consideration of unaudited Financial Results for the quarter ended June 30 2025 and Dividend. The Board of Directors of the Company at its meeting held today, August 4, 2025, has, inter alia, considered and approved: - 1. the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Reports issued by the Statutory Auditors. 2. the payment of interim dividend of 400% i.e. Rs.4.00 (Rupee Four only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has fixed August 8, 2025, as the Record Date for the purpose of payment of Interim Dividend and the same will be paid on or before August 21, 2025. (As Per BSE Announcement Dated on:04.08.2025) | ||
| Board Meeting | 26 May 2025 | 16 May 2025 |
| Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve Intimation of Board meeting to be held on May 26 2025 to consider Audited Financial Results for the fourth quarter and financial year ended March 31 2025. Intimation of appointment of Secretarial Auditors (As Per BSE Announcement dated on 26.05.2025) | ||
| Board Meeting | 6 Feb 2025 | 17 Jan 2025 |
| AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve Intimation of Board Meeting to be held on February 6 2025 to consider and approve inter alia the standalone and consolidated Unaudited financials results of the company for the third quarter and Nine months period ended December 312024 Intimation of outcome of the Board meeting held on February 6, 2025 (As Per Bse Announcement Dated on 06.02.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.